Fifty-eight Nigerian outpatients with documented erectile dysfunction (ED) received open-label sildenafil citrate (Viagra s ) for 8 weeks. The 50-mg starting dose could be adjusted to 100 or 25 mg based on response and tolerability. The International Index of Erectile Function (IIEF) Questionnaire, a global efficacy question, and intercourse data recorded in a patient event log were used to assess efficacy. Frequency of penetration and maintained erection were both significantly enhanced (Po0.0001); 95% of patients reported improved erections and 81% of all attempts at intercourse were successful. Orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction also improved significantly (Po0.0001). The most frequent adverse events (all-cause) were headache (17%) and myalgia (3%); only one patient discontinued treatment because of headache, which was considered unrelated to sildenafil. Oral sildenafil significantly improved erectile function and was well tolerated in this trial of Nigerian men suffering from ED. Our results are consistent with reports from other countries.
Introduction
Sildenafil citrate (Viagra s ) is an oral agent that effectively treats erectile dysfunction (ED) by increasing blood flow to the penis, thus enhancing normal vasodilator erectile mechanisms. During sexual stimulation, release of nitric oxide in the corpora cavernosa 1 activates the enzyme guanylate cyclase, which produces increased levels of cyclic guanosine monophosphate (cGMP). This nucleotide, which is responsible for smooth-muscle relaxation in the corpora cavernosa, allows inflow of blood and penile erection. 2, 3 Sildenafil is a highly selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5), which degrades cavernosal cGMP. 4 By inhibiting this enzyme, sildenafil allows buildup of cGMP in the corpora cavernosa and hence facilitates erection. Because proper activation of the nitric-oxide-generating pathways is necessary for this build-up, sildenafil has no effect when these pathways are not activated; therefore, sexual stimulation is required for the drug's beneficial effect on erectile mechanisms. Acting at a local level, sildenafil has proven efficacy in the treatment of ED of organic, psychogenic, and mixed etiologies. 5 Efficacy and safety data for sildenafil have been limited primarily to North American and European patients. To determine whether these findings are representative of men at large, we used a placebo-baseline-controlled, open-label, flexible dose-escalation design to evaluate sildenafil in a heterogeneous population similar to that encountered in a local community-based practice in Nigeria. Dose escalation allowed each patient to be treated with optimal efficacy and tolerability.
Methods
Fifty-eight male outpatients with documented ED for more than 6 months were evaluated at six sites in Nigeria from September 1998 to May 1999. Patients were 18 years or older and in a stable relationship with their partners for at least the past 6 months. Men were excluded from the study if their history indicated genital anatomic deformities that would significantly impair erection (eg, severe penile fibrosis) or other sexual disorders considered to be the primary diagnosis with coexisting ED. Other exclusion criteria included any major psychiatric disorder not well controlled with treatment; alcoholism or substance abuse; major hematological, renal, or hepatic abnormalities; ED following a spinal cord injury; unstable or poorly controlled diabetes mellitus; stroke or myocardial infarction; significant cardiovascular disease or any other clinically significant abnormalities; recent use of medications known to be causally associated with ED (beta blockers, thiazide diuretics, digoxin, tricyclic antidepressants, finasteride) or anticipated changes to such therapy during the study; and current use of nitrates or nitric oxide donors in any form. Vacuum devices, intracavernosal injection, or any other medications or therapies for ED (including testosterone) were discontinued for the duration of the study.
All patients provided written informed consent. The study was approved by an Independent Ethics Committee at each site and complied with the principles of the 1996 revised Declaration of Helsinki and with local laws and regulations defining clinical research in Nigeria.
Following a 4-week placebo run-in, during which baseline data on sexual function were collected, patients entered an 8-week open-label, flexible dose-escalation period. Sildenafil was supplied as 25-, 50-, and 100-mg oral tablets. All patients were prescribed an initial 50-mg dose to be taken approximately 1 h prior to anticipated sexual activity during the first 2 weeks of treatment. Thereafter, the dose was adjusted (to 100 or 25 mg) at the investigator's discretion according to efficacy and tolerability guidelines. Observed or reported adverse events were recorded at each study visit.
Patients completed an event log each time they took a dose of sildenafil or engaged in sexual activity, recording the dose taken (if any), whether or not associated with an attempt at sexual intercourse, whether sexual stimulation occurred, and whether the erection was of sufficient rigidity or duration to complete the sexual activity. The International Index of Erectile Function (IIEF), a 15-item, self-administered sexual function questionnaire, 6 was completed at the end of the placebo runin and at the end of active treatment. A global efficacy question ('Has the treatment improved your erections?') was answered at study end. Statistical analyses were performed by means of the single sample t-test, and any P-value less than 0.05 was statistically significant.
Results
In all, 58 patients received study medication. Three patients (5.2%) withdrew: one was lost to follow-up, the second withdrew consent, and the third discontinued because of an adverse event. In total, 23 patients (39.7%) had at least one ongoing disease on entry. Table 1 lists demographic characteristics for  all patients. In all, 56 of the 58 patients who received study drug were included in the intent-to-treat analysis. The two primary efficacy end points, frequency of erection (IIEF question 3) and frequency of maintained erection (IIEF question 4), were both significantly improved from baseline (Po0.0001) with sildenafil, as were all IIEF domain scores (Po0.0001). Table 2 summarizes responses to the IIEF sexual function questionnaire. According to the event log, a mean of 16.5% of attempts at sexual intercourse were successful during the placebo runin compared with 80.7% during sildenafil treatment, which also improved the quality of their erections in 94.6% of the men, as determined by the global efficacy question.
Analysis of responses to a quality-of-life questionnaire demonstrated statistically significant improvements between baseline and last observation (week 8) scores for six of the eight life satisfaction questions (Table 3) .
In all, 15 (25.9%) of the 58 patients experienced treatment-emergent adverse events, but in only six (10.3%) patients were these events judged to be treatment related (Table 4 ). The most common adverse event was headache. The two cases (3.4%) of myalgia were unrelated to sildenafil, as were most other adverse events, which were mild. One patient (1.7%) permanently discontinued (sildenafil 50 mg) because of a severe headache, assessed by the investigator as unrelated to treatment. No serious adverse events occurred during the study.
Discussion
ED involves several potential causative mechanisms that can show varying degrees of interdependence. Treatment must therefore take into account the multifactorial nature of the disease, the demographic heterogeneity of the affected population, and the coexisting medical conditions, as well as the potential for interaction of concomitant medications. Although this was an open-label study, and as such cannot be readily compared to other placebocontrolled studies, it is the first of its kind solely in black African men. The study evaluated sildenafil in a population similar to that encountered in a local community-based practice in Nigeria.
Our results mirrored the excellent efficacy of sildenafil documented in previous open-label studies. Frequency of penetration and of maintained erection (the primary efficacy end points), as well as the five IIEF domains, showed significant improvement. Proportions of successful attempts at intercourse and of patients reporting an improvement in the quality of their erections further demonstrated effectiveness.
Treatment was well tolerated, and no serious safety concerns were identified. The overall incidence of adverse events was low. Headache was the most frequently reported adverse event, and was usually transient and mild. The agent's vasodilator effects may explain the incidence of headache, which reflects the known pharmacological properties of the compound.
One patient noted an episode of mild visual 'haziness' that resolved after 1 h. Transient visual disturbances have occurred in a small number of patients in other studies and are related to inhibition by sildenafil of retinal PDE type 6. 7 No cases of priapism and no serious adverse events were encountered.
Conclusions
In this open-label, flexible dose-escalation trial, the first of its kind in black African men, oral sildenafil, taken as required prior to anticipated sexual activity, was an effective, well-tolerated treatment for ED in male outpatients in Nigeria. These results are consistent with findings in other studies around the world. 
